Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,789.70 | 43.80 | 0.50% |
| CAC 40 | 7,941.64 | 69.16 | 0.88% |
| DAX 40 | 21,727.20 | 89.67 | 0.41% |
| Dow JONES (US) | 44,882.13 | 168.61 | 0.38% |
| FTSE 100 | 8,646.88 | 89.07 | 1.04% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,681.75 | 49.43 | 0.25% |
| Nikkei 225 | 39,627.83 | 113.86 | 0.29% |
| NZX 50 Index | 12,995.01 | 66.63 | 0.52% |
| S&P 500 | 6,071.17 | 31.86 | 0.53% |
| S&P/ASX 200 | 8,532.30 | 38.60 | 0.45% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |